GPC3 affects the prognosis of lung adenocarcinoma and lung squamous cell carcinoma

BMC Pulmonary Medicine

Table 4 Correlation of GPC3 expression with the clinical phenotypes of lung squamous cell carcinoma (LUSC) samples

Characteristics	Variable	Number of patients	GPC3 expression				Test	P value
Characteristics	Variable	Number of patients	High	Percent (%)	Low	Percent (%)	Test	P value
Age	≥ 65	355	183	64.9	172	66.4	Wilcoxon	0.9002
	< 65	186	99	35.1	87	33.6
Location	Central Lung	157	83	57.2	74	65.5	Wilcoxon	0.3471
	Peripheral Lung	101	62	42.8	39	34.5
years_smoked	≥ 53	177	146	59.1	141	65	Wilcoxon	0.2589
	< 53	287	101	40.9	76	35
pathologic_M	M0	443	0	0	1	0.4	Kruskal	0.5125
	M1	6	0	0	1	0.4
	M1a	1	1	0.3	5	1.9
	M1b	1	235	82.2	208	80.3
	MX	94	50	17.5	44	17
pathologic_N	N0	352	1	0.3	6	2.3	Kruskal	0.4514
	N1	143	189	65.4	163	62.5
	N2	43	73	25.3	70	26.8
	N3	5	22	7.6	21	8
	NX	7	4	1.4	1	0.4
pathologic_T	T1	53	15	5.2	11	4.2	Kruskal	0.1308
	T1a	26	20	6.9	24	9.2
	T1b	44	59	20.4	41	15.7
	T2	187	14	4.8	10	3.8
	T2a	100	26	9	14	5.4
	T2b	40	96	33.2	91	34.9
	T3	76	34	11.8	42	16.1
	T4	24	25	8.7	28	10.7
Radiation therapy	Yes	51	24	10.4	27	13.1	Wilcoxon	0.2045
	No	386	207	89.6	179	86.9
Gender	Female	144	216	74.7	190	72.8	Wilcoxon	0.4309
	Male	406	73	25.3	71	27.2
Tumor stage	I	270	144	50.2	126	48.6	Kruskal	0.3464
	II	179	1	0.3	7	2.7
	III	89	94	32.8	85	32.8
	IV	8	48	16.7	41	15.8

ISSN: 1471-2466